Teva's U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy Lipitor Deal The Israel-based manufacturer saw its full-year U.S. generic revenues drop 32% due to expired marketing exclusivities and manufacturing problems at two plants. However, the fourth quarter brought a rebound, thanks to launches of generic Zyprexa and Combivir and a profit-sharing agreement on atorvastatin.
"Arimidex Direct" Program Will Provide Branded Cancer Drug To U.S. Patients For $40 A Month Spurred on by patient requests for affordable access to the branded version of now generic anastrozole, AstraZeneca will partner with Express Scripts to provide the drug direct to patients at a fixed co-payment.
Challenging Lucentis: Eylea's Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012 Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.
Acorda Expands Pipeline With Neuronex And New Ampyra Indications Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it's pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.
"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here
